<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755949</url>
  </required_header>
  <id_info>
    <org_study_id>12-001686</org_study_id>
    <nct_id>NCT01755949</nct_id>
  </id_info>
  <brief_title>Colchicine and CRP in Atrial Fibrillation and AF Ablation</brief_title>
  <official_title>Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Detiger Funds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the
      rise in CRP which occurs following atrial fibrillation ablation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups of patients will be randomized to colchicine 0.6 mg PO bis in die (BID) or
      matching placebo:

        1. Paroxysmal atrial fibrillation, pre-ablation

        2. Persistent atrial fibrillation, pre-ablation

        3. Chronic persistent atrial fibrillation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 6, 2016</completion_date>
  <primary_completion_date type="Actual">December 6, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-reactive Protein</measure>
    <time_frame>baseline, day 28</time_frame>
    <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Atrial Fibrillation</measure>
    <time_frame>day 28</time_frame>
    <description>All subjects will have 12 lead ECG on day 28 to measure the number of subjects with normal sinus rhythm and atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of C-reactive Protein Levels</measure>
    <time_frame>baseline, day 3, day 7, day 14, day 28</time_frame>
    <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo. Subjects not undergoing ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID. Subjects undergoing ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo. Subjects undergoing ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, AF, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID. Subjects undergoing ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, AF, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo. Subjects undergoing ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine, 0.6 mg PO BID</intervention_name>
    <description>Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo</description>
    <arm_group_label>Chronic atrial fibrillation, colchicine</arm_group_label>
    <arm_group_label>Pre-ablation, AF, colchicine</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm, colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug</description>
    <arm_group_label>Chronic atrial fibrillation, placebo</arm_group_label>
    <arm_group_label>Pre-ablation, AF, placebo</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices.
             Diagnosis of AF will be made based on the 12 -lead surface ECG.

          -  Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology
             laboratory for the procedure in sinus rhythm..

          -  Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in
             the electrophysiology laboratory in atrial fibrillation .

        Exclusion Criteria:

          1. Abnormal liver function with elevated enzymes&gt; 1.5 times the normal.

          2. Abnormal kidney function with glomerular filtration rate &lt; 50 ml/min

          3. Increased levels of creatine kinase or known myopathy

          4. Neutropenia

          5. Known GI disorders

          6. Women of childbearing age who have not had surgical sterilization and are not using
             oral contraceptives, or who's spouse has not had surgical sterilization will be
             excluded due to the length of the trial and the possibility that they could become
             pregnant after entry.

          7. Pregnant and lactating women

          8. Lactose intolerance

          9. Known sensitivity, allergy, or contraindication to colchicine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L. Blackshear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant in Cardiovascular Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <results_first_submitted>January 12, 2018</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph L. Blackshear</investigator_full_name>
    <investigator_title>Principal Investiator</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>colchicine</keyword>
  <keyword>c reactive protein</keyword>
  <keyword>CRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chronic Atrial Fibrillation, Colchicine</title>
          <description>Colchicine 0.6 mg PO bis in die (BID)
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Subjects not undergoing ablation.</description>
        </group>
        <group group_id="P2">
          <title>Chronic Atrial Fibrillation, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Subjects not undergoing ablation.</description>
        </group>
        <group group_id="P3">
          <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.</description>
        </group>
        <group group_id="P4">
          <title>Pre-ablation, Sinus Rhythm, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Subjects undergoing ablation.</description>
        </group>
        <group group_id="P5">
          <title>Pre-ablation, AF, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Subjects undergoing ablation.</description>
        </group>
        <group group_id="P6">
          <title>Pre-ablation, AF, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Subjects undergoing ablation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chronic Atrial Fibrillation, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects not undergoing ablation.</description>
        </group>
        <group group_id="B2">
          <title>Chronic Atrial Fibrillation, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects not undergoing ablation.</description>
        </group>
        <group group_id="B3">
          <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.</description>
        </group>
        <group group_id="B4">
          <title>Pre-ablation, Sinus Rhythm, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects undergoing ablation.</description>
        </group>
        <group group_id="B5">
          <title>Pre-ablation, AF, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.</description>
        </group>
        <group group_id="B6">
          <title>Pre-ablation, AF, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects undergoing ablation.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="7"/>
                    <measurement group_id="B2" value="73" spread="8"/>
                    <measurement group_id="B3" value="65" spread="5"/>
                    <measurement group_id="B4" value="69" spread="6"/>
                    <measurement group_id="B5" value="68" spread="7"/>
                    <measurement group_id="B6" value="62" spread="18"/>
                    <measurement group_id="B7" value="68" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in C-reactive Protein</title>
        <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
        <time_frame>baseline, day 28</time_frame>
        <population>Not all subjects had sample available at all timepoints to measure C-reactive protein levels. Sample was either not collected or insufficient volume to run assay.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Atrial Fibrillation, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O2">
            <title>Chronic Atrial Fibrillation, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O3">
            <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O4">
            <title>Pre-ablation, Sinus Rhythm, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O5">
            <title>Pre-ablation, AF, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O6">
            <title>Pre-ablation, AF, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein</title>
          <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
          <population>Not all subjects had sample available at all timepoints to measure C-reactive protein levels. Sample was either not collected or insufficient volume to run assay.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="7.2"/>
                    <measurement group_id="O2" value="2.7" spread="2.9"/>
                    <measurement group_id="O3" value="2.9" spread="1.6"/>
                    <measurement group_id="O4" value="5.9" spread="5.5"/>
                    <measurement group_id="O5" value="2.6" spread="2.7"/>
                    <measurement group_id="O6" value="2.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.0"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                    <measurement group_id="O3" value="1.0" spread="0.7"/>
                    <measurement group_id="O4" value="2.5" spread="1.7"/>
                    <measurement group_id="O5" value="1.2" spread="1.0"/>
                    <measurement group_id="O6" value="5.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Baseline C-reactive protein vs day 28 C-reactive protein</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline C-reactive protein vs day 28 C-reactive protein</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>difference between placebo and colchicine levels at day 28</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Atrial Fibrillation</title>
        <description>All subjects will have 12 lead ECG on day 28 to measure the number of subjects with normal sinus rhythm and atrial fibrillation.</description>
        <time_frame>day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chronic Atrial Fibrillation, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O2">
            <title>Chronic Atrial Fibrillation, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O3">
            <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O4">
            <title>Pre-ablation, Sinus Rhythm, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O5">
            <title>Pre-ablation, AF, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O6">
            <title>Pre-ablation, AF, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Atrial Fibrillation</title>
          <description>All subjects will have 12 lead ECG on day 28 to measure the number of subjects with normal sinus rhythm and atrial fibrillation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Sinus rhythm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Atrial fibrillation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>placebo vs colchicine</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of C-reactive Protein Levels</title>
        <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
        <time_frame>baseline, day 3, day 7, day 14, day 28</time_frame>
        <population>Not all subjects had sample available at all timepoints to measure C-reactive protein levels. Sample was either not collected or insufficient volume to run assay.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Atrial Fibrillation, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O2">
            <title>Chronic Atrial Fibrillation, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects not undergoing ablation.</description>
          </group>
          <group group_id="O3">
            <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O4">
            <title>Pre-ablation, Sinus Rhythm, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O5">
            <title>Pre-ablation, AF, Colchicine</title>
            <description>Colchicine 0.6 mg, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
          <group group_id="O6">
            <title>Pre-ablation, AF, Placebo</title>
            <description>Placebo tablets, encapsulated to be indistinguishable from active drug, twice daily for 28 days Subjects undergoing ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of C-reactive Protein Levels</title>
          <description>Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.</description>
          <population>Not all subjects had sample available at all timepoints to measure C-reactive protein levels. Sample was either not collected or insufficient volume to run assay.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="7.2"/>
                    <measurement group_id="O2" value="2.7" spread="2.9"/>
                    <measurement group_id="O3" value="2.9" spread="1.6"/>
                    <measurement group_id="O4" value="5.9" spread="5.5"/>
                    <measurement group_id="O5" value="2.6" spread="2.7"/>
                    <measurement group_id="O6" value="2.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="5.1"/>
                    <measurement group_id="O2" value="2.9" spread="2.2"/>
                    <measurement group_id="O3" value="24.9" spread="19.5"/>
                    <measurement group_id="O4" value="27.8" spread="2.82"/>
                    <measurement group_id="O5" value="4.4" spread="1.1"/>
                    <measurement group_id="O6" value="48.2" spread="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="4.8"/>
                    <measurement group_id="O2" value="3.2" spread="2.2"/>
                    <measurement group_id="O3" value="5.0" spread="2.2"/>
                    <measurement group_id="O4" value="6.6" spread="5.8"/>
                    <measurement group_id="O5" value="1.9" spread="1.2"/>
                    <measurement group_id="O6" value="15.4" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="7.8"/>
                    <measurement group_id="O2" value="3.2" spread="2.3"/>
                    <measurement group_id="O3" value="1.9" spread="1.2"/>
                    <measurement group_id="O4" value="4.1" spread="3.0"/>
                    <measurement group_id="O5" value="2.0" spread="1.9"/>
                    <measurement group_id="O6" value="5.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.0"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                    <measurement group_id="O3" value="1.0" spread="0.7"/>
                    <measurement group_id="O4" value="2.5" spread="1.7"/>
                    <measurement group_id="O5" value="1.2" spread="1.0"/>
                    <measurement group_id="O6" value="5.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chronic Atrial Fibrillation, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects not undergoing ablation.</description>
        </group>
        <group group_id="E2">
          <title>Chronic Atrial Fibrillation, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects not undergoing ablation.</description>
        </group>
        <group group_id="E3">
          <title>Pre-ablation, Sinus Rhythm, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.</description>
        </group>
        <group group_id="E4">
          <title>Pre-ablation, Sinus Rhythm, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects undergoing ablation.</description>
        </group>
        <group group_id="E5">
          <title>Pre-ablation, AF, Colchicine</title>
          <description>Colchicine 0.6 mg PO BID
Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.</description>
        </group>
        <group group_id="E6">
          <title>Pre-ablation, AF, Placebo</title>
          <description>Matching placebo
Matching placebo: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug Subjects undergoing ablation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was halted in 2015 due to departure of study staff; shortly thereafter Takeda Inc announced it could not renew production of colchicine nor support the study after the end of 2016. Principal investigator elected to terminate enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph L. Blackshear, Principal Investigator</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>904-953-7279</phone>
      <email>blackshear.joseph@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

